You must be a subscriber to see the full results of your search.
Please log in or subscribe below if you are not already a subscriber.
The Daily News subscribers get full access to more than
million names and addresses along with powerful search and download features.
Get the business leads you need with powerful searches of public records and notices.
Download listings into your spreadsheet or database.
Learn more about our services
| Search again
Editorial Results (free)
1. Eli’s Coming
- Thursday, April 23, 2015
“Once again, as Eli swung around the dark trees and onto the lawn, the children fled.” – Philip Roth, in “Eli, the Fanatic” (1959).
2. Imminent Danger
- Wednesday, February 11, 2015
The risk is real. And the evidence is in the charges of second-degree murder against the owner of New England Compounding Center Inc., and pharmacists and others employed by the company.
3. AstraZeneca Rejects $119 Billion Offer From Pfizer
- Tuesday, May 20, 2014
LONDON (AP) – The board of AstraZeneca on Monday rejected the improved $119 billion takeover offer from U.S. drugmaker Pfizer, a decision that caused a sharp slide in the U.K. company's share price as many investors think it effectively brings an end to the protracted and increasingly bitter takeover saga.
4. Lilly Diabetes Drug Meets Late-Stage Goal
- Wednesday, February 26, 2014
INDIANAPOLIS (AP) – Eli Lilly and Co.'s experimental injectable diabetes treatment dulaglutide fared on par in a late-stage study with another drug that's already on the market.
The Indianapolis drugmaker said Tuesday that a once-weekly, 1.5-milligram dose of dulaglutide was not inferior to a daily, 1.8 milligram dose of Novo Nordisk's Victoza in a study of nearly 600 patients who were already taking metformin, an older diabetes treatment. A non-inferior finding essentially means that the drug did not show superiority or inferiority to the other treatment. That determination was the main goal of the study.
5. Companies Need to Think Like Venture Capitalists
- Wednesday, March 27, 2013
Last week we discussed the concept of the intrapreneur and our conviction that companies must add the pressures of failure and constrained resources to get ingenuity. Real entrepreneurs have vision, resilience and fortitude. Their natural drive, focus on survival and ability to pivot with the market is what generates market winners. It is the natural selection process at work. This is why VCs think the team is most critical, and companies looking to innovate should too.
6. Gammon Joins Methodist in Business Development
- Wednesday, December 05, 2012
Myra Gammon has joined Methodist Le Bonheur Healthcare as a business development account manager for Community Care Associates. In her new role, Gammon is responsible for the development and management of the Occupational Health and Wellness Services program.
7. 10 Drugmakers Team Up to Improve Testing Process
- Thursday, September 20, 2012
TRENTON, N.J. (AP) – Pharmaceutical industry heavyweights are teaming up to address a challenge that's long vexed drugmakers: how to improve the way experimental drugs are tested so they can get approved, and reach patients, faster.
8. Inspector Highlights Psych Drug Use Among Elderly
- Thursday, December 01, 2011
WASHINGTON (AP) – Government inspectors told lawmakers Wednesday that Medicare officials needs to do more to stop doctors from prescribing powerful psychiatric drugs to nursing home patients with dementia, an unapproved practice that has flourished despite repeated government warnings.
9. FDA Approves First Diabetes-Cholesterol Combo Pill
- Monday, October 10, 2011
TRENTON, N.J. (AP) – The first combination pill for the millions of people with the dangerous combination of diabetes and high cholesterol won U.S. approval Friday, offering convenience – and savings – to patients taking multiple pills.
10. Senate Bill Aims to Combat Pharmaceutical Theft
- Wednesday, March 09, 2011
WASHINGTON (AP) – Law enforcement officials would have more leeway to pursue and punish criminals who steal prescription pharmaceuticals under a proposal introduced Tuesday by Senate lawmakers.
11. UTHSC Signs on for Eli Lilly Initiative
- Friday, October 01, 2010
The University of Tennessee Health Science Center is participating in a research program initiated by Eli Lilly and Co. to get first dibs on potential drug therapies.
12. Pressure Mounts to Stop Antibiotics in Agriculture
- Monday, January 04, 2010
FRANKENSTEIN, Mo. (AP) – The mystery started the day farmer Russ Kremer got between a jealous boar and a sow in heat.
The boar gored Kremer in the knee with a razor-sharp tusk. The burly pig farmer shrugged it off, figuring: “You pour the blood out of your boot and go on.”
13. GlaxoSmithKline Changes Doctor Training Policy
- Tuesday, September 22, 2009
TRENTON, N.J. (AP) - British drugmaker GlaxoSmithKline PLC said Monday it is making major changes in its funding of educational programs for doctors, reducing the number it sponsors and switching its focus to independent ones with balanced information.
14. Housing, Jobless Data Point To Fragile Recovery
- Friday, September 18, 2009
WASHINGTON (AP) – Housing construction rose in August and the number of newly laid-off workers seeking unemployment aid fell unexpectedly last week, adding to signs the recession has ended.
Still, the reports suggested a slow and fragile economic recovery. In part, that’s because the increased housing starts were due solely to a surge in construction of apartment buildings – while the much larger single-family homes sector fell for the first time in six months. And jobless claims remain far above the levels associated with a healthy economy.
15. Drug Industry, Pfizer Lead in Health Lobbying
- Wednesday, July 22, 2009
WASHINGTON (AP) - The drug industry's trade group and one of the nation's biggest pharmaceutical companies reported spending more money than other health care organizations on lobbying in the second quarter of this year.
16. Medtronic To Disclose Physician Payments
- Wednesday, February 25, 2009
NEW YORK (AP) – Following years of pressure, medical device maker Medtronic Inc. will begin disclosing how much money it gives physicians in various consulting and other payments, though the reporting threshold is far less than currently proposed legislation.
17. Report: US Drug Sales Growth Heads Toward New Low
- Thursday, October 30, 2008
WASHINGTON (AP) - U.S. sales of pharmaceuticals will grow at the slowest rate on record this year, as the weakening economy compounds other factors hampering the industry, according to a report issued Wednesday.
18. Bristol-Myers Triples 3Q Profit on Business Sale
- Friday, October 24, 2008
TRENTON, N.J. (AP) - Bristol-Myers Squibb Co. said Thursday its third-quarter profit tripled, mainly because of a big gain from selling its high-tech wound care business.
19. Eli Lilly Settles Zyprexa Inquiries in 32 States
- Wednesday, October 08, 2008
NEW YORK (AP) - Eli Lilly & Co. said Tuesday it will pay $62 million to resolve investigations into the marketing and promotion of its antipsychotic drug Zyprexa in 32 states and Washington, D.C.
20. Eli Lilly Agrees to Buy ImClone for Over $6B
- Tuesday, October 07, 2008
INDIANAPOLIS (AP) - Eli Lilly & Co. has agreed to buy biotechnology company ImClone Systems Inc. for more than $6 billion in a deal that would expand Lilly's cancer treatment pipeline a few years before several patent expirations hit the drug maker.
21. Senators Pressure Medtronic To Disclose Consulting Info.
- Monday, October 06, 2008
Senate lawmakers are pressuring Medtronic to disclose more about its consulting arrangements with physicians, citing prior allegations the company paid kickbacks to surgeons to boost sales of spinal implants.
22. Medtronic’s Hawkins Takes on Larger Role
- Wednesday, July 16, 2008
The head of one of Memphis’ leading biotech companies will expand his role in August, following in the footsteps of a predecessor with dual roles.
Minneapolis-based Medtronic Inc. president and CEO William A. Hawkins has been named chairman in addition to his current roles, effective Aug. 21.
23. Archived Article: Benchmark
- Thursday, April 18, 2002
Some drug earnings Some drug earnings under the weather Stricken by patent expirations, too few new drugs in the pipeline and political uncertainty, the drug industry is a bit anemic, with first-quarter earnings growth averaging 3 percent, analysts ...